# Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

> **NCT00689936** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 1623 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide and low-dose dexamethasone
- **DRUG:** Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
- **DRUG:** Melphalan, Prednisone and Thalidomide

## Key facts

- **NCT ID:** NCT00689936
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-21
- **Primary completion:** 2016-07-14
- **Final completion:** 2016-07-14
- **Target enrollment:** 1623 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689936, "Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00689936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*